Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 6/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24614230 | 0.90 | HDAC4 (0.64) | HDAC4HDAC1HDAC6HDAC3HDAC7 | |
| SCHEMBL30423206 | 0.87 | HDAC1 (0.57) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL30540151 | 0.87 | HDAC4 (0.72) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL17866901 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL12035399 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL4320872 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL4320879 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL12035396 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL22286471 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 | |
| SCHEMBL12035758 | 0.83 | HDAC4 (0.58) | HDAC4HDAC1SMN1; SMN2HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | HDAC4 855/4885HDAC1 604/4885SMN1; SMN2 4587/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | HDAC4 851/4885HDAC1 627/4885SMN1; SMN2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.